Psoriasis
https://en.wikipedia.org/wiki/Psoriasis
☆ AI Dermatology — Free ServiceI te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu. relevance score : -100.0%
References
Psoriasis 28846344 NIH
Phototherapy 33085287 NIH
Tumor Necrosis Factor Inhibitors 29494032 NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).
Ka taea e nga momo maimoatanga te awhina i nga tohu. Ko enei maimoatanga ko nga kirimini steroid, te kirimiri huaora D3, te rama ultraviolet, me nga rāau immunosuppressive, penei i te methotrexate. Tata ki te 75 % o te urunga o te kiri ka pai ake mā te kirīmi anake. He maha nga momo rongoā koiora kei te whakawhanakehia mō te maimoatanga o te psoriasis.
Ko te Psoriasis he mate autoimmune kare kawea, ka pā te mate ki te 2‑4 % o te taupori. He rite te auau o ngā tāne me ngā wahine. Ka timata pea te mate i ngā tau katoa, engari ka timata i te pakeketanga. Ka pā te arthritis psoriatic (psoriatic arthritis) ki te 30 % o ngā tangata whai psoriasis.
○ Maimoatanga – Rongoā OTC
Ka taea e te rā te awhina i te psoriasis nā te mea ka whakaawehia e te rā ngā huringa immunological ki ngā turoro me te psoriasis. Ka awhina pea te hinu hydrocortisone ki te rongoā i ētahi mate iti o te psoriasis.
#OTC steroid ointment
○ Maimoatanga
Ko te Psoriasis he mate autoimmune mau tonu, he maha ngā rongoā kei te akohia. Ko koiora te mea tino whai hua engari tino utu.
#High potency steroid ointment
#Calcipotriol cream
#Phototherapy
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)